BRPI0707904A8 - Disfarce gustativo de fluoroquinolonas aerossolizadas - Google Patents

Disfarce gustativo de fluoroquinolonas aerossolizadas

Info

Publication number
BRPI0707904A8
BRPI0707904A8 BRPI0707904A BRPI0707904A BRPI0707904A8 BR PI0707904 A8 BRPI0707904 A8 BR PI0707904A8 BR PI0707904 A BRPI0707904 A BR PI0707904A BR PI0707904 A BRPI0707904 A BR PI0707904A BR PI0707904 A8 BRPI0707904 A8 BR PI0707904A8
Authority
BR
Brazil
Prior art keywords
disgustation
gustatory
bacterial infections
aerosolized fluoroquinolones
fluoroquinolone
Prior art date
Application number
BRPI0707904A
Other languages
English (en)
Inventor
Surber Mark
Bostian Keith
Lomovskaya Olga
Griffith David
Dudley Mike
Original Assignee
Mpex Pharmaceuticals Inc
Tripex Pharmaceuticals Llc
Raptor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mpex Pharmaceuticals Inc, Tripex Pharmaceuticals Llc, Raptor Pharmaceuticals Inc filed Critical Mpex Pharmaceuticals Inc
Publication of BRPI0707904A2 publication Critical patent/BRPI0707904A2/pt
Publication of BRPI0707904A8 publication Critical patent/BRPI0707904A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

DISFARCE GUSTATIVO DE FLUOROQUINOLONAS AEROSSOLIZADAS. São reveladas aqui formulações de fluoroquinolonas apropriadas para aerossolizaçâo e uso de tais formulações para administração era aerossol de antimicrobianos de fluoroquinolona para o tratamento de infecções bacterianas pulmonares. Em particular, é descrito o levofloxacin inalado, especificamente formulado e distribuído para infecções bacterianas dos pulmões. Os métodos incluem protocolo de inalação e procedimentos de fabricação para produção e uso das composições descritas.
BRPI0707904A 2006-02-13 2007-02-12 Disfarce gustativo de fluoroquinolonas aerossolizadas BRPI0707904A8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77330006P 2006-02-13 2006-02-13
US77330106P 2006-02-13 2006-02-13
US60/773,301 2006-02-13
US60/773,300 2006-02-13
US11/436,875 2006-05-18
US11/436,875 US7838532B2 (en) 2005-05-18 2006-05-18 Aerosolized fluoroquinolones and uses thereof
PCT/US2007/003649 WO2007095156A2 (en) 2006-02-13 2007-02-12 Taste masking of aerosolized fluoroquinolones

Publications (2)

Publication Number Publication Date
BRPI0707904A2 BRPI0707904A2 (pt) 2011-05-17
BRPI0707904A8 true BRPI0707904A8 (pt) 2017-05-02

Family

ID=38230310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707904A BRPI0707904A8 (pt) 2006-02-13 2007-02-12 Disfarce gustativo de fluoroquinolonas aerossolizadas

Country Status (3)

Country Link
US (1) US7838532B2 (pt)
BR (1) BRPI0707904A8 (pt)
WO (1) WO2007095156A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392389T3 (es) 2004-05-17 2012-12-10 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2644613A1 (en) * 2006-03-07 2007-09-13 Endacea, Inc. Compositions and methods for treating respiratory disorders
WO2008116165A2 (en) * 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
US8747872B2 (en) * 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
WO2009136408A1 (en) * 2008-04-09 2009-11-12 Institute Of Life Sciences Synergistic pharmaceutical cocrystals
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
SI2346509T1 (sl) * 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
US20110238602A1 (en) * 2008-11-13 2011-09-29 Azouri Ilan Ovadia Method for enhanced marketing of vibration medicine products and coaching therefrom
JP5960434B2 (ja) * 2009-02-18 2016-08-02 アラダイム コーポレーション 肺送達のためのｐＨ調節された製剤
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
ES2755754T3 (es) 2009-04-24 2020-04-23 Horizon Orphan Llc Métodos para tratar una infección pulmonar bacteriana mediante el uso de fluoroquinolonas
WO2011022074A1 (en) * 2009-08-19 2011-02-24 Mpex Pharmaceuticals, Inc. Riboflavin based aerosol and use as placebo in trials
WO2011022075A1 (en) * 2009-08-19 2011-02-24 Mpex Pharmaceuticals, Inc. Use of aerosolized antibiotics for treating chronic obstructive pulmonary disease
CN101627999B (zh) * 2009-08-20 2011-05-04 山东罗欣药业股份有限公司 一种巴洛沙星组合物及其制备方法、及原料药的合成方法
BR112012004692B8 (pt) 2009-09-04 2021-05-25 Mpex Pharmaceuticals Inc solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
WO2011094504A2 (en) * 2010-01-28 2011-08-04 Ora, Inc. Antimicrobial sinus irrigation compositions, methods, and devices
US20130164351A1 (en) * 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
JP5877201B2 (ja) 2010-08-30 2016-03-02 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CN103228273B (zh) 2010-09-29 2017-04-05 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2013112865A1 (en) * 2012-01-27 2013-08-01 The Trustees Of The University Of Pennsylvania Diagnosis and treatment for respiratory tract diseases
CA2865972C (en) * 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
RU2765231C2 (ru) 2012-04-04 2022-01-26 Интервет Интернэшнл Б.В. Мягкие жевательные фармацевтические продукты
EP2877164B1 (en) 2012-07-24 2023-07-05 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds
CA2904388C (en) * 2013-03-08 2023-09-26 Research Institute At Nationwide Children's Hospital Transcutaneous dosage formulation
ES2753244T3 (es) * 2013-03-15 2020-04-07 Univ Degli Studi Di Milano Bicocca Compuestos novedosos 1,2,4 oxadiazol activos contra patógenos gram positivos
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
US20140377357A1 (en) * 2013-06-19 2014-12-25 Professional Compounding Centers Of America Poloxamer Based Inhalation Composition
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US20150283070A1 (en) * 2014-04-08 2015-10-08 Sansa Corporation (Barbados) Inc. Nicotine Formulations and Methods of Making the Same
WO2016140219A1 (ja) 2015-03-02 2016-09-09 武田薬品工業株式会社 ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法
CN111110641B (zh) * 2018-10-31 2022-03-01 长春海悦药业股份有限公司 一种左氧氟沙星片剂组合物及其制备方法
CN109679503B (zh) * 2018-12-28 2021-01-08 中山市天图精细化工有限公司 宠物粑粑固化气雾剂
EP3980373A1 (en) 2019-06-04 2022-04-13 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
CA3142109A1 (en) 2019-06-04 2020-12-10 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
GB2610722A (en) 2020-04-23 2023-03-15 Thirty Respiratory Ltd Nitric oxide or nitric oxide releasing compositions for use in treating SARS-COV and SARS-COV-2
CN112957322B (zh) * 2021-03-23 2023-08-15 回音必集团江西东亚制药有限公司 一种乳酸左氧氟沙星氯化钠注射液及其制备方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NO166131C (no) * 1985-06-20 1991-06-05 Daiichi Seiyaku Co Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
ES2102393T3 (es) * 1989-12-29 1997-08-01 Abbott Lab Complejos de acido quinolona carboxilico--ion metalico--acido.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5258528A (en) * 1990-11-30 1993-11-02 Warner-Lambert Company Individual stereoisomers of pyrrolidine methanamines substituted on the ring nitrogen by a 1-phenylethyl group
WO1992022288A1 (en) 1991-06-10 1992-12-23 Schering Corporation Non-chlorofluorocarbon aerosol formulations
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
CA2176298C (en) * 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
US6579854B1 (en) * 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6406880B1 (en) * 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6884784B1 (en) * 1997-05-06 2005-04-26 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6664239B2 (en) * 1997-05-06 2003-12-16 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US20030082107A1 (en) 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
GB9810299D0 (en) 1998-05-15 1998-07-15 Glaxo Group Ltd Use of nitric oxide synthase inhibitors
AU761040B2 (en) * 1998-08-21 2003-05-29 Kyorin Pharmaceutical Co. Ltd. Aqueous liquid preparations
EP1115417B1 (en) * 1998-09-25 2006-04-05 Cubist Pharmaceuticals, Inc. Use of daptomycin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
CA2282066C (en) * 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6294178B1 (en) * 1999-11-01 2001-09-25 Robert E. Weinstein Method and device for coordinating topical and oral sinusitis treatments
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6667057B2 (en) * 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6669948B2 (en) * 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663890B2 (en) * 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6663891B2 (en) * 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6667042B2 (en) * 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6608078B2 (en) * 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7326691B2 (en) * 2004-06-21 2008-02-05 Nektar Therapeutics Compositions comprising amphotericin B, methods, and systems
US6716819B2 (en) * 2000-05-19 2004-04-06 University Of Iowa Research Foundation Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6492328B2 (en) * 2000-06-28 2002-12-10 The University Of Iowa Research Foundation Novispirins: antimicrobial peptides
US6503953B2 (en) * 2000-07-26 2003-01-07 Atopic Pty Ltd. Methods for treating atopic disorders
EP1313708A1 (en) 2000-08-29 2003-05-28 Chiron Corporation Quinoline antibacterial compounds and methods of use thereof
ATE319710T1 (de) * 2000-12-21 2006-03-15 Pharmacia & Upjohn Co Llc Antimikrobielle chinolonderivate und ihre verwendung zur behandlung bakterieller infektionen
BR0207930A (pt) 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
US6878713B2 (en) * 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6589955B2 (en) * 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
US20030138403A1 (en) * 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
SI1273292T1 (en) * 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
WO2003051300A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
US20030171340A1 (en) * 2002-02-07 2003-09-11 Jenefir Isbister Methods of disease treatment using metal-complexed tetracycline antibiotics
WO2003075890A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
US20040152701A1 (en) * 2002-12-02 2004-08-05 Dr. Reddy's Laboratories Limited Novel anhydrous crystalline form of Levofloxacin and process for preparation there of
CN1735620A (zh) * 2002-12-16 2006-02-15 兰贝克赛实验室有限公司 纯的左氧氟沙星半水合物和它的制备方法
EP1589943A2 (en) * 2003-01-09 2005-11-02 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
CA2536918A1 (en) * 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
ES2327935T3 (es) * 2003-11-17 2009-11-05 Nektar Therapeutics Introduccion de un aerosol en un circuito de un ventilador.
WO2005089738A2 (en) 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7148404B2 (en) * 2004-05-04 2006-12-12 Novozymes A/S Antimicrobial polypeptides
AU2005245962A1 (en) * 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
US7632869B2 (en) * 2004-05-24 2009-12-15 Bausch & Lomb Incorporated Antimicrobial compositions and uses thereof
WO2006011051A1 (en) 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
WO2006033713A2 (en) 2004-08-09 2006-03-30 Chiron Corporation Methods for ciprofloxacin inhalation
US7388077B2 (en) * 2004-11-12 2008-06-17 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding the same
AU2006206359B2 (en) 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
EP1871910A4 (en) * 2005-04-05 2009-07-29 Scripps Research Inst COMPOSITIONS AND METHODS FOR IMPROVING DRUG SENSITIVITY AND TREATING DRUG-RESISTANT INFECTIONS AND DISEASES
PT2594272T (pt) 2005-05-18 2018-07-31 Horizon Orphan Llc Fluoroquinolonas aerossolizadas e suas utilizações
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
MX2008000131A (es) * 2005-07-01 2008-04-04 Cinv Ag Dispositivos medicos que comprenden un material compuesto reticulado.
US7547692B2 (en) * 2005-12-14 2009-06-16 Activbiotics Pharma, Llc Rifamycin analogs and uses thereof
WO2007085057A1 (en) 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
WO2007090123A2 (en) 2006-01-30 2007-08-09 University Of Chicago Mgra is a redox regulator of antibiotic sensitivity and virulence
WO2007090646A1 (en) 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
EP2028936A4 (en) 2006-02-13 2014-02-26 Univ Boston COMPOSITIONS AND METHODS FOR POTENTIATING ANTIBIOTICS AND DISCOVERING DRUGS
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy

Also Published As

Publication number Publication date
US7838532B2 (en) 2010-11-23
WO2007095156A3 (en) 2007-12-21
US20060276483A1 (en) 2006-12-07
BRPI0707904A2 (pt) 2011-05-17
WO2007095156A2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
BRPI0707904A8 (pt) Disfarce gustativo de fluoroquinolonas aerossolizadas
MX359219B (es) Fluoroquinolonas aerosolizadas y sus usos.
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
MX345158B (es) Formulaciones de fluoroquinolona en aerosol para farmacocinetica mejorada.
CU23284B7 (es) Tiotropium novedoso conteniendo polvo inhalador
MX2010004673A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
MX2007012802A (es) Composicion farmaceutica en aerosol.
PT1267866E (pt) Tratamento de doencas respiratorias
MX2007010072A (es) Derivados de piperidina antibacterianos.
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TNSN05186A1 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
NO20054180L (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
IL189270A (en) Repamycins converted to phosphonate and their derivatives, pharmaceutical preparations containing them and their use in the prevention and treatment of bone and joint infections
TR201000681A2 (tr) İnhalasyon yoluyla alınan kuru toz formülasyonları.
BR112022019519A2 (pt) Tratamento
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
WO2008004100A3 (en) Therapeutic compounds
MX2010012019A (es) Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.
EP2323656A4 (en) PHARMACEUTICAL PRODUCT USING A MUSCARIN RECEPTOR ANTAGONIST AND A BETA-2 ADRENOZEPTORAGONIST
WO2005041922A3 (en) Composition
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: MPEX PHARMACEUTICALS, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020080151552/RJ DE 09/12/2008.

B25A Requested transfer of rights approved

Owner name: TRIPEX PHARMACEUTICALS, LLC (US)

B25A Requested transfer of rights approved

Owner name: RAPTOR PHARMACEUTICALS INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL